Description
SWOT ANALYSIS OF MYLAN
Mylan
Parent Company
Mylan Pharmaceuticals
Category
Pharmaceuticals
Sector
Healthcare
Tagline/ Slogan
Seeing is believing
USP
It is third largest generics manufacturing company in U.S
STP
API, nebulized respiratory or severe allergy medications & anti Segment retroviral drugs
Healthcare professionals & doctors providing solutions in ART, Target Group respiratory diseases
Mylan is the company, which innovates to satisfy the unmet medical Positioning need & aims to provide 7 billion people of world medical solutions.
SWOT Analysis
1. Mylan has strong generic portfolio with more than 1000 individual products 2. It has strong global presence in more than 150 countries 3. Their major strength is vertically integrated supply chain 4. Mylan has acquired generic business of Merck & Matrix pharmaceuticals which is largest generic Manufacturer in India Strength 5. It has more than 15,000 well trained employees
1. Alleged litigations have sometimes impacted its public image Weakness 2. Very limited portion of its revenue comes from foreign business
1. Expiry of patent on Lipitor has open new business opportunities 2. Increasing awareness about healthcare Opportunity 3. Increasing prevalence of chronic diseases such as cancer
Threats
1. Global economic slowdown
2. More stringent patent protection laws 3.Pending litigations
Competition
1. Teva pharmaceuticals 2. Barr pharmaceuticals 3. Sandoz Competitors 4. Dr. Reddy’s laboratories
doc_766260498.docx
SWOT ANALYSIS OF MYLAN
Mylan
Parent Company
Mylan Pharmaceuticals
Category
Pharmaceuticals
Sector
Healthcare
Tagline/ Slogan
Seeing is believing
USP
It is third largest generics manufacturing company in U.S
STP
API, nebulized respiratory or severe allergy medications & anti Segment retroviral drugs
Healthcare professionals & doctors providing solutions in ART, Target Group respiratory diseases
Mylan is the company, which innovates to satisfy the unmet medical Positioning need & aims to provide 7 billion people of world medical solutions.
SWOT Analysis
1. Mylan has strong generic portfolio with more than 1000 individual products 2. It has strong global presence in more than 150 countries 3. Their major strength is vertically integrated supply chain 4. Mylan has acquired generic business of Merck & Matrix pharmaceuticals which is largest generic Manufacturer in India Strength 5. It has more than 15,000 well trained employees
1. Alleged litigations have sometimes impacted its public image Weakness 2. Very limited portion of its revenue comes from foreign business
1. Expiry of patent on Lipitor has open new business opportunities 2. Increasing awareness about healthcare Opportunity 3. Increasing prevalence of chronic diseases such as cancer
Threats
1. Global economic slowdown
2. More stringent patent protection laws 3.Pending litigations
Competition
1. Teva pharmaceuticals 2. Barr pharmaceuticals 3. Sandoz Competitors 4. Dr. Reddy’s laboratories
doc_766260498.docx